Could a chemo drug tame rare vascular tumors?
NCT ID NCT03331250
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This small pilot study tested the drug eribulin (Halaven) in 13 people with two rare cancers of blood vessels: angiosarcoma and epithelioid hemangioendothelioma (EHE). The goal was to see if the drug could shrink tumors or stop them from growing. Participants had already tried at least one other treatment. The study is now complete and no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Eribulin (Halaven)
- What this could lead to
- If it works, this could point toward a treatment option for rare blood vessel cancers like angiosarcoma and EHE.
- What could go wrong
- This is a very small pilot study with only 13 participants, so results may not apply broadly. The drug may not shrink tumors or improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug targets rare cancer that often defies treatment
- New drug cocktail targets rare, aggressive cancer
- New pill may keep soft tissue sarcoma in check after chemo
- New combo therapy aims to shrink sarcomas
- New Two-Drug immune attack launched against tough cancers
- New cocktail aims to shrink sarcomas: bevacizumab joins chemo in phase 2 trial